TMS
TMS is a Tokyo-based clinical-stage biotech company that unlocks fungus-derived SMTP small molecule compound group. SMTPs have novel dual mode of action, both thrombolytic and anti-inflammatory. The lead compound TMS-007 is in Phase IIa clinical trial indicated for acute ischemic stroke and partnered with Biogen.
TMS
Industry:
Biotechnology Life Science Medical Nursing And Residential Care Pharmaceutical
Founded:
2005-02-17
Address:
Fuchu, Tokyo, Japan
Country:
Japan
Website Url:
http://www.tms-japan.co.jp
Total Employee:
11+
Status:
Active
Contact:
+81-42-306-5087
Email Addresses:
[email protected]
Total Funding:
910.25 M JPY
Technology used in webpage:
SPF Font Awesome Apache
Similar Organizations
Axcella
Axcella is a biotechnology company providing therapeutics development solutions.
Current Employees Featured
Founder
Investors List
77 Capital
77 Capital investment in Venture Round - TMS
Nissay Capital
Nissay Capital investment in Series C - TMS
Oita Venture Capital
Oita Venture Capital investment in Series C - TMS
Mitsubishi UFJ Capital
Mitsubishi UFJ Capital investment in Series C - TMS
Tohoku University Venture Partners
Tohoku University Venture Partners investment in Series C - TMS
Sansei Capital Investment
Sansei Capital Investment investment in Series C - TMS
MITSUI SUMITOMO INSURANCE Venture Capital (MSIVC)
MITSUI SUMITOMO INSURANCE Venture Capital (MSIVC) investment in Series C - TMS
KSP
KSP investment in Convertible Note - TMS
Mitsubishi UFJ Capital
Mitsubishi UFJ Capital investment in Convertible Note - TMS
Japan Asia Investment
Japan Asia Investment investment in Convertible Note - TMS
